Abstracts tagged "Macrophage"

Abstract Number: 3217 • 2015 ACR/ARHP Annual Meeting
Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus
Jessica Doerner¹, Samantha Chalmers² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Kidney and skin involvement are common in systemic lupus erythematosus (SLE). Nephritis is seen in up to 60% of patients, and contributes significantly to…
Abstract Number: 935 • 2015 ACR/ARHP Annual Meeting
Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1
Quan-Bo Zhang^1,2, Jing-Guo Zhou³, Cong-Cong Yin¹, Yu-Feng Qing⁴, Chang-Gui Li⁵, Li Zhou¹ and Qing-Sheng Mi⁶, ¹Immunology Program, Department of Dermatology, Henry Ford Health System, Detroit, MI, ²Geriatrics, Affliated hospital of North Sichuan Medical College, Nanchong, China, ³Department of Rheumatology and Immunology, Affliated hospital of North Sichuan Medical College, Nanchong, China, ⁴Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nanchong, China, ⁵Affiliated Hospital of Qingdao University, Qingdao, China, ⁶Immunology, Dermatology, Henry Ford Health System, Detroit, MI
Background/Purpose: MicroRNAs (miRNAs) have been shown to serve as important regulators for inflammatory and immune responses and are implicated in several immune disorders including gouty…
Abstract Number: 1160 • 2015 ACR/ARHP Annual Meeting
DNA Hydroxylmethylation Regulates Pro-Inflammatory Cytokine Expression in Macrophages
Fangfang Sun^1,2, Renate E. Gay¹, Beat A. Michel¹, Shuang Ye², Steffen Gay¹, Michel Neidhart¹ and Emmanuel Karouzakis¹, ¹University Hospital Zurich, Center of Experimental Rheumatology, Switzerland, Zurich, Switzerland, ²Department of Rheumatology, South Campus, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China
Background/Purpose: Activated macrophages are found in the inflamed and hyperplasic synovial RA tissues. Macrophages are the main producers of high levels of pro-inflammatory cytokines such…
Abstract Number: 1169 • 2015 ACR/ARHP Annual Meeting
Crossregulatory Mechanisms Between Synovial Fibroblasts and Macrophages Relevant in RA Pathogenesis
Jennifer Ding¹, Lionel B. Ivashkiv² and Laura T. Donlin¹, ¹Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Macrophages and synovial fibroblasts function as key drivers of inflammation in rheumatoid arthritis (RA). We have developed a co-culture system that aims to define…
Abstract Number: 1401 • 2015 ACR/ARHP Annual Meeting
Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?
César Antonio Egües Dubuc, Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, Olga Maiz Alonso, Iñaki Hernando Rubio and Joaquin Maria Belzunegui Otano, Rheumatology, Donostia University Hospital, Donostia, Spain
Background/Purpose: Macrophage activation syndrome (MAS) is a group of diseases, especially autoimmune (AI) and hemato-oncology (HO). So it will be interesting to find any clinical…
Abstract Number: 1402 • 2015 ACR/ARHP Annual Meeting
Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Baruch Goldberg¹, Eyal Muscal², Marietta De Guzman³ and Carl Allen⁴, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Hematology and Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal pathologic inflammatory process resulting from impaired immune function due to inherited gene mutations or secondary to…
Abstract Number: 1625 • 2015 ACR/ARHP Annual Meeting
Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling
Patricia Ruiz-Limon, Yolanda Jiménez Gómez, Carlos Perez-Sanchez, MariCarmen Abalos-Aguilera, M.Ángeles Aguirre Zamorano, Jerusalem Calvo-Gutierrez, Rafaela Ortega, Eduardo Collantes-Estévez, Alejandro Escudero-Contreras, Chary Lopez-Pedrera and Nuria Barbarroja, IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain
Background/Purpose: Macrophages play a key role in the pathogenesis of the rheumatoid arthritis (RA). Under certain stimulus conditions these cells are able to switch their…
Abstract Number: 1209 • 2014 ACR/ARHP Annual Meeting
Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase
Hao Li^1,2, Qi Wu¹, PingAr Yang¹, Zheng Wang³, Jun Li¹, Bao Luo¹, Jeffrey C. Edberg¹, Hui-Chen Hsu¹, John D. Mountz^1,4 and Robert P. Kimberly on behalf of PROFILE investigators⁵, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, ⁴Birmingham VA Medical Center, Birmingham, AL, ⁵Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Ibrutinib, a Btk kinase activity inhibitor, is a novel inhibitor under development for autoimmune disease therapy. We have shown that Btk was significantly upregulated…
Abstract Number: 1197 • 2014 ACR/ARHP Annual Meeting
Febuxostat Inhibits Monosodium Urate Crystal-Induced IL-1beta Secretion and Cell Death Via ROS- and Intracellular ATP-Dependent Pathways
Johji Nomura¹, Nathalie Busso², Mizuho Tamura¹, Tsunefumi Kobayashi¹ and Alexander So³, ¹Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo, Japan, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose: In gout, monosodium urate (MSU) crystals trigger acute inflammation. MSU has been reported to activate NLRP3 inflammasome via ROS-dependent pathways, which result in IL-1beta…
Abstract Number: 1199 • 2014 ACR/ARHP Annual Meeting
Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Rik Schelbergen¹, Wouter de Munter², Martijn van den Bosch³, Floris Lafeber⁴, Annet Sloetjes³, Thomas Vogl⁵, Johannes Roth⁵, Peter M. van der Kraan⁶, Arjen B. Blom³, Wim B van den Berg³ and Peter L. van Lent³, ¹Radboud university medical center, Nijmegen, Netherlands, ²Experimental rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose The main pathological feature of osteoarthritis (OA) is degradation of the articular cartilage. Other important hallmarks include subclinical inflammation of the synovium and ectopic…
Abstract Number: 969 • 2014 ACR/ARHP Annual Meeting
Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation
Alexander Misharin¹, Carla M. Cuda², Luisa Morales-Nebreda³, Gokhan Mutlu¹, GR Scott Budinger³ and Harris R. Perlman⁴, ¹Northwestern University, Chicago, IL, ²Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Pulmonary fibrosis has emerged as the leading cause of death in patients with Systemic Sclerosis (SSc). Currently available therapies are only marginally effective in…
Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting
Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
María Galindo¹, Elena Gonzalo-Gil², Oscar Toldos³, Carmen García-Herrero², Alicia Usategui¹, Sonia Pérez-Yagüe⁴, Gabriel Criado⁵, Domingo F. Barber⁴ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, ⁴Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
Abstract Number: 438 • 2014 ACR/ARHP Annual Meeting
Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease
Tsuyoshi Shirai¹, Eric L. Matteson², David G. Harrison³, Barbara B. Wallis⁴, Themistocles L. Assimes⁵, Jorg J. Goronzy⁶ and Cornelia M. Weyand¹, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ⁴Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Patients with RA have an increased risk of developing coronary artery disease (CAD) compared to the general population. The underlying pathological process of CAD…
Abstract Number: 327 • 2014 ACR/ARHP Annual Meeting
AMPK Activation in Inflammatory Arthritis
Monica Guma¹, Yun Wang² and Ru Liu-Bryan², ¹Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ²UCSD/VAMC, La Jolla, CA
Background/Purpose: AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase involved in the regulation of cellular energy homeostasis. It is a central regulator of both…
Abstract Number: 76 • 2014 ACR/ARHP Annual Meeting
Identification of Synovial Genes and Pathways Associated with Disease Progression in a Cohort of Early Symptomatic Osteoarthritis Patients Using a Transcriptomic Approach
Arjen B. Blom¹, Peter L. van Lent¹, Martijn H. van den Bosch², Hans Cats³, Frank H.J. van den Hoogen⁴, Floris P.J.G. Lafeber⁵, Wim B. van den Berg¹ and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ³Hengstdal 3, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: If and how the synovial activation that is observed in over 50% of osteoarthritis (OA) patients contributes to irreversible joint pathology, is not known.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.